Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Hitachi beefs up regenerative medicine

by Jean-François Tremblay
March 27, 2017 | A version of this story appeared in Volume 95, Issue 13

Hitachi Chemical will pay $75 million to buy all the shares that it doesn’t already own in the cell therapy firm PCT. A year ago, Hitachi had paid $20 million for a 20% stake in the firm. Now majority-owned by Caladrius Biosciences, PCT is a contract manufacturer of cells used in regenerative medicine. Hitachi, which is building a cell manufacturing plant in Yokohama, Japan, says full ownership of PCT will help it expand globally in the regenerative medicine business. PCT runs facilities in several countries.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.